Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

• Published in: Cephalalgia Vol. 38; no. 8; pp. 1442 - 1454
• Main Authors: Skljarevski, Vladimir, Matharu, Manjit, Millen, Brian A, Ossipov, Michael H, Kim, Byung-Kun, Yang, Jyun Yan
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.07.2018
• Subjects: LY2951742; Episodic migraine; MIDAS; galcanezumab; MSQ; headache; humanized monoclonal antibody; CGRP

Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention. Methods A global, double-blind, 6-month study of patients with episodic migraine was undertaken with 915 intent-to-treat patients randomized to monthly galcanezumab 120...